Transdermal Skin Patches Market

Executive Summary

Transdermal Skin Patches Market was valued at US $7.62 billion in 2021 and is projected to grow at 5.48% CAGR over the forecast period to reach US $10.49 billion by 2027. Transdermal Skin Patches Market represented US $0.77 billion opportunity over 2019-2021 and estimated to create US $2.87 billion opportunity in 2027 over 2021.

Transdermal Skin Patches from Consainsights analyses the Transdermal Skin Patches Market in the Life Sciences industry over the forecast period to 2027.

Transdermal Skin Patches research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Transdermal Skin Patches segmentation includes Type, Application and Geography.

Based on the Type, the Transdermal Skin Patches analysis covers Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Matrix, Other Types.

In Type segment, Single-layer Drug-in-Adhesive segment has highest cagr growth of 4.85%.

Based on the Application, the Transdermal Skin Patches analysis covers Pain Relief, Smoking Reduction and Cessation Aid, Overactive Bladder, Hormonal Therapy, Other Applications.

In Application segment, Pain Relief segment has highest cagr growth of 4.85%.

Based on the region, the Transdermal Skin Patches analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Teva Pharmaceutical Industries Ltd., Novartis AG​, Teikoku Pharma USA Inc. (Teikoku Seiyaku Co. Ltd)​, Mylan NV (Viatris), 3M Company, Luye Pharma Group​, Purdue Pharma Manufacturing LP, Henan Lingrui Pharmaceutical Ltd, Samyang Biopharmaceuticals Corp. (Samyang Holdings) and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, Single-layer Drug-in-Adhesive segment has the highest revenue of US $3.40 billion and is expected to grow at CAGR of 4.85% by 2027 Single-layer Drug-in-Adhesive segment has highest cagr growth of 4.85%.

Single-layer Drug-in-Adhesive

Single-layer Drug-in-Adhesive segment was valued at US $3.05 billion in 2019 and is projected to grow at 4.85% CAGR over the forecast period to reach US $4.68 billion by 2027. Single-layer Drug-in-Adhesive segment represented US $0.34 billion opportunity over 2019-2021 and estimated to create US $1.28 billion opportunity in 2027 over 2021.

Multi-layer Drug-in-Adhesive

Multi-layer Drug-in-Adhesive segment was valued at US $1.87 billion in 2019 and is projected to grow at 4.85% CAGR over the forecast period to reach US $2.87 billion by 2027. Multi-layer Drug-in-Adhesive segment represented US $0.21 billion opportunity over 2019-2021 and estimated to create US $0.78 billion opportunity in 2027 over 2021.

Matrix

Matrix segment was valued at US $1.39 billion in 2019 and is projected to grow at 4.85% CAGR over the forecast period to reach US $2.13 billion by 2027. Matrix segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.58 billion opportunity in 2027 over 2021.

Other Types

Other Types segment was valued at US $0.53 billion in 2019 and is projected to grow at 4.85% CAGR over the forecast period to reach US $0.82 billion by 2027. Other Types segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.22 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Pain Relief segment has the highest revenue of US $3.53 billion and is expected to grow at CAGR of 4.85% by 2027 Pain Relief segment has highest cagr growth of 4.85%.

Pain Relief

Pain Relief segment was valued at US $3.17 billion in 2019 and is projected to grow at 4.85% CAGR over the forecast period to reach US $4.86 billion by 2027. Pain Relief segment represented US $0.36 billion opportunity over 2019-2021 and estimated to create US $1.33 billion opportunity in 2027 over 2021.

Smoking Reduction and Cessation Aid

Smoking Reduction and Cessation Aid segment was valued at US $1.78 billion in 2019 and is projected to grow at 4.85% CAGR over the forecast period to reach US $2.73 billion by 2027. Smoking Reduction and Cessation Aid segment represented US $0.20 billion opportunity over 2019-2021 and estimated to create US $0.75 billion opportunity in 2027 over 2021.

Overactive Bladder

Overactive Bladder segment was valued at US $0.85 billion in 2019 and is projected to grow at 4.85% CAGR over the forecast period to reach US $1.31 billion by 2027. Overactive Bladder segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.36 billion opportunity in 2027 over 2021.

Hormonal Therapy

Hormonal Therapy segment was valued at US $0.55 billion in 2019 and is projected to grow at 4.85% CAGR over the forecast period to reach US $0.85 billion by 2027. Hormonal Therapy segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.23 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $0.48 billion in 2019 and is projected to grow at 4.85% CAGR over the forecast period to reach US $0.74 billion by 2027. Other Applications segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.20 billion opportunity in 2027 over 2021.